Barinthus Biotherapeutics Plc. - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Barinthus Biotherapeutics Plc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for autoimmune and inflammatory diseases using its SNAP-TI platform. The company's lead candidate, VTP-1000 (celiac disease), is in Phase 1 trials. The company is currently a "smaller reporting company" and an "emerging growth company."
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(5.5) million | $(19.7) million |
| Net Loss Per Share (Basic/Diluted) | $(0.14) | $(0.49) |
| Operating Expenses | $6.1 million | $20.9 million |
| Cash, Cash Equivalents & Restricted Cash | $67.2 million | $100.6 million |
| Net Cash Used in Operating Activities | $(3.4) million | $(14.9) million |
| Accumulated Deficit | $(309.6) million | $(257.3) million |
Material Changes vs. Prior Period
- Significant Expense Reduction: Total operating expenses decreased by $14.8 million (71%) compared to Q1 2025. This was driven by a $4.7 million decrease in R&D expenses and a $10.1 million decrease in General and Administrative (G&A) expenses.
- R&D Shift: Direct R&D spend on "Barinthus Legacy Assets" (infectious disease and oncology) dropped by $1.0 million due to strategic deprioritization, while spend on the lead candidate VTP-1000 increased by $0.4 million.
- Foreign Exchange Impact: G&A expenses benefited from a $3.0 million foreign exchange gain in Q1 2026, compared to a $4.4 million loss in Q1 2025, largely due to USD/GBP fluctuations.
- Facility Closure: The closure of the U.K. laboratory in Q3 2025 resulted in reduced facility costs and accelerated depreciation/impairment charges in the prior year, contributing to lower current period expenses.
- Transaction Costs: The company incurred $3.7 million in transaction-related legal and advisory fees in Q1 2026 related to the proposed merger with Clywedog Therapeutics, Inc.
Guidance, Outlook, and Risks
- Merger with Clywedog: The company is pursuing a merger with Clywedog Therapeutics, Inc., expected to close in mid-2026. Upon closing, the combined entity will be renamed "Clywedog Therapeutics Holdings, Inc." and trade under the ticker "CLYD."
- Liquidity: Management expects existing cash resources ($67.2 million) to fund operations for at least the next 12 months on a standalone basis. However, the company expects to incur losses for the foreseeable future and may require additional financing if the merger does not close or if operational needs increase.
- Strategic Focus: The company has deprioritized infectious disease and oncology programs to focus on Immunology and Inflammation (I&I). It intends to exit the CEPI Funding Agreement for the VTP-500 (MERS) program.
- Risks: Key risks include the failure to consummate the merger, inability to raise additional capital, clinical trial failures, and regulatory hurdles. The company also faces foreign currency translation risks due to significant operations in the U.K.
Investor Verification Checklist
- Merger Status: Verify the current status of the Clywedog merger agreement, including shareholder approval timelines and regulatory conditions.
- Cash Runway: Confirm the burn rate and whether the $67.2 million cash balance is sufficient to sustain operations through the merger closing or until new funding is secured.
- Grant Repayment: Review the $1.0 million repayment obligation to CEPI and the remaining restricted cash balance of $1.3 million.
- Contingent Consideration: Monitor the $3.0 million liability related to the Avidea acquisition and the potential for up to $40.0 million in additional milestone payments.
- UK Operations: Assess the impact of the U.K. laboratory closure on future R&D capabilities and lease obligations.